Clinical trial of lincomycin hydrochloride in Reiter's disease.
A double-blind trial comparing lincomycin hydrochloride (Mycivin) and placebo in 22 patients with Reiter's disease showed no significant difference in clinical or laboratory findings between the two groups. It is concluded that lincomycin hydrochloride is no more effective than placebo in the treatment of Reiter's disease.
D000328:Adult; D016918:Arthritis, Reactive / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D001799:Blood Sedimentation; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007592:Joint Diseases / Q000209:etiology; D007958:Leukocyte Count; D008034:Lincomycin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010919:Placebos
D010919:Placebos; D008034:Lincomycin